RGLS Nov 2024 2.500 call
| Previous close | 0.7500 |
| Open | 0.7500 |
| Bid | 0.2500 |
| Ask | 0.9000 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.7500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 57 |
PR NewswireRegulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24t
- PR Newswire
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer effective May 16, 2024. Dr. Garg previously served as the Company's Senior Vice President, Clinical Development and Regulatory.
- PR Newswire
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
